Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2303 vs Rituximab with CHOP in Untreated DLBCL
NCT03777085Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Overall Response Rate at 18 weeks. Status: unknown.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03777085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03777085.